Cargando…

Impact of cumulative exposure to high-dose oral glucocorticoids on fracture risk in Denmark: a population-based case-control study

SUMMARY: We examined the effect of cumulative exposure to high doses of oral glucocorticoids on fracture risk. Compared to short-course users (daily dose ≥ 15 mg + cumulative < 1 g), heavy users (daily dose ≥ 15 mg + cumulative dose ≥ 1 g) had the highest risk of fracture. These patients should b...

Descripción completa

Detalles Bibliográficos
Autores principales: Amiche, M. Amine, Abtahi, Shahab, Driessen, Johanna H. M., Vestergaard, Peter, de Vries, Frank, Cadarette, Suzanne M., Burden, Andrea M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer London 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5857556/
https://www.ncbi.nlm.nih.gov/pubmed/29552730
http://dx.doi.org/10.1007/s11657-018-0424-x
_version_ 1783307485274177536
author Amiche, M. Amine
Abtahi, Shahab
Driessen, Johanna H. M.
Vestergaard, Peter
de Vries, Frank
Cadarette, Suzanne M.
Burden, Andrea M.
author_facet Amiche, M. Amine
Abtahi, Shahab
Driessen, Johanna H. M.
Vestergaard, Peter
de Vries, Frank
Cadarette, Suzanne M.
Burden, Andrea M.
author_sort Amiche, M. Amine
collection PubMed
description SUMMARY: We examined the effect of cumulative exposure to high doses of oral glucocorticoids on fracture risk. Compared to short-course users (daily dose ≥ 15 mg + cumulative < 1 g), heavy users (daily dose ≥ 15 mg + cumulative dose ≥ 1 g) had the highest risk of fracture. These patients should be monitored for fracture management strategies. PURPOSE: The effect of cumulative exposure to high daily doses of oral glucocorticoids on fracture risk remains debated. We therefore aimed to examine the hip fracture risk associated with short courses and heavy use of high-dosed oral glucocorticoids. METHODS: We conducted a population-based case-control study using the Danish National Health Service data, 1996–2011. Cases were those aged ≥ 18 years who sustained a hip (primary outcome) fracture (n = 81,342). Vertebral and forearm fractures were considered in secondary analyses. Controls (matched 1:1) were those without a fracture. Average daily dose (DD) and total cumulative dose (CD) were calculated among current oral glucocorticoid users. Among patients with a high daily dose (DD ≥ 15 mg), we identified short-course users as those with a CD < 1 g and heavy users as those with a CD ≥ 1 g. We estimated adjusted odds ratio (adj.OR) of fracture with current glucocorticoid use compared to never-use, using conditional logistic regression. RESULTS: A high DD (≥ 15 mg) and high CD (≥ 1 g) were independently associated with an increased hip fracture risk (adj.OR 2.5; 95% CI 2.2–2.9; adj.OR 1.6; 95% CI 1.5–1.8, respectively). However, the risk was substantially increased among heavy users (DD ≥ 15 mg and CD ≥ 1 g: adj.OR 2.9; 95% CI 2.5–3.4) as compared to short-course users (DD ≥ 15 mg and CD < 1 g: adj.OR 1.4; 95% CI 1.1–1.9). Associations were stronger for vertebral fractures, yet little association was identified for forearm fractures. CONCLUSION: Among patients receiving a high DD (≥ 15 mg), heavy users (≥ 1 g CD) showed the most substantial increase in hip fracture risk. Among those receiving high DD, a threshold of 1 g CD may identify heavy users that are candidates for focused fracture management services. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s11657-018-0424-x) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5857556
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Springer London
record_format MEDLINE/PubMed
spelling pubmed-58575562018-03-21 Impact of cumulative exposure to high-dose oral glucocorticoids on fracture risk in Denmark: a population-based case-control study Amiche, M. Amine Abtahi, Shahab Driessen, Johanna H. M. Vestergaard, Peter de Vries, Frank Cadarette, Suzanne M. Burden, Andrea M. Arch Osteoporos Original Article SUMMARY: We examined the effect of cumulative exposure to high doses of oral glucocorticoids on fracture risk. Compared to short-course users (daily dose ≥ 15 mg + cumulative < 1 g), heavy users (daily dose ≥ 15 mg + cumulative dose ≥ 1 g) had the highest risk of fracture. These patients should be monitored for fracture management strategies. PURPOSE: The effect of cumulative exposure to high daily doses of oral glucocorticoids on fracture risk remains debated. We therefore aimed to examine the hip fracture risk associated with short courses and heavy use of high-dosed oral glucocorticoids. METHODS: We conducted a population-based case-control study using the Danish National Health Service data, 1996–2011. Cases were those aged ≥ 18 years who sustained a hip (primary outcome) fracture (n = 81,342). Vertebral and forearm fractures were considered in secondary analyses. Controls (matched 1:1) were those without a fracture. Average daily dose (DD) and total cumulative dose (CD) were calculated among current oral glucocorticoid users. Among patients with a high daily dose (DD ≥ 15 mg), we identified short-course users as those with a CD < 1 g and heavy users as those with a CD ≥ 1 g. We estimated adjusted odds ratio (adj.OR) of fracture with current glucocorticoid use compared to never-use, using conditional logistic regression. RESULTS: A high DD (≥ 15 mg) and high CD (≥ 1 g) were independently associated with an increased hip fracture risk (adj.OR 2.5; 95% CI 2.2–2.9; adj.OR 1.6; 95% CI 1.5–1.8, respectively). However, the risk was substantially increased among heavy users (DD ≥ 15 mg and CD ≥ 1 g: adj.OR 2.9; 95% CI 2.5–3.4) as compared to short-course users (DD ≥ 15 mg and CD < 1 g: adj.OR 1.4; 95% CI 1.1–1.9). Associations were stronger for vertebral fractures, yet little association was identified for forearm fractures. CONCLUSION: Among patients receiving a high DD (≥ 15 mg), heavy users (≥ 1 g CD) showed the most substantial increase in hip fracture risk. Among those receiving high DD, a threshold of 1 g CD may identify heavy users that are candidates for focused fracture management services. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s11657-018-0424-x) contains supplementary material, which is available to authorized users. Springer London 2018-03-18 2018 /pmc/articles/PMC5857556/ /pubmed/29552730 http://dx.doi.org/10.1007/s11657-018-0424-x Text en © The Author(s) 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Article
Amiche, M. Amine
Abtahi, Shahab
Driessen, Johanna H. M.
Vestergaard, Peter
de Vries, Frank
Cadarette, Suzanne M.
Burden, Andrea M.
Impact of cumulative exposure to high-dose oral glucocorticoids on fracture risk in Denmark: a population-based case-control study
title Impact of cumulative exposure to high-dose oral glucocorticoids on fracture risk in Denmark: a population-based case-control study
title_full Impact of cumulative exposure to high-dose oral glucocorticoids on fracture risk in Denmark: a population-based case-control study
title_fullStr Impact of cumulative exposure to high-dose oral glucocorticoids on fracture risk in Denmark: a population-based case-control study
title_full_unstemmed Impact of cumulative exposure to high-dose oral glucocorticoids on fracture risk in Denmark: a population-based case-control study
title_short Impact of cumulative exposure to high-dose oral glucocorticoids on fracture risk in Denmark: a population-based case-control study
title_sort impact of cumulative exposure to high-dose oral glucocorticoids on fracture risk in denmark: a population-based case-control study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5857556/
https://www.ncbi.nlm.nih.gov/pubmed/29552730
http://dx.doi.org/10.1007/s11657-018-0424-x
work_keys_str_mv AT amichemamine impactofcumulativeexposuretohighdoseoralglucocorticoidsonfractureriskindenmarkapopulationbasedcasecontrolstudy
AT abtahishahab impactofcumulativeexposuretohighdoseoralglucocorticoidsonfractureriskindenmarkapopulationbasedcasecontrolstudy
AT driessenjohannahm impactofcumulativeexposuretohighdoseoralglucocorticoidsonfractureriskindenmarkapopulationbasedcasecontrolstudy
AT vestergaardpeter impactofcumulativeexposuretohighdoseoralglucocorticoidsonfractureriskindenmarkapopulationbasedcasecontrolstudy
AT devriesfrank impactofcumulativeexposuretohighdoseoralglucocorticoidsonfractureriskindenmarkapopulationbasedcasecontrolstudy
AT cadarettesuzannem impactofcumulativeexposuretohighdoseoralglucocorticoidsonfractureriskindenmarkapopulationbasedcasecontrolstudy
AT burdenandream impactofcumulativeexposuretohighdoseoralglucocorticoidsonfractureriskindenmarkapopulationbasedcasecontrolstudy